Ocugen (OCGN) Income towards Parent Company (2014 - 2026)
Ocugen (OCGN) reported Income towards Parent Company of -$19.1 million for Q1 2026, down 23.3% on a YoY basis from -$24.8 million in Q1 2025, and down 4.69% quarter-over-quarter from -$18.2 million in Q4 2025.
Ocugen (OCGN) Income towards Parent Company (2014 - 2026) Analysis & Trends
Ocugen has reported Income towards Parent Company for 13 years, with the latest figure at -$19.1 million in Q1 2026.
- For the quarter ending Q1 2026, Income towards Parent Company fell 23.3% year-over-year to -$19.1 million; the trailing twelve-month figure through Mar 2026 stood at -$70.8 million (down 22.71% YoY), and the FY2025 full-year result was -$67.2 million, down 23.97% from the prior year.
- Income towards Parent Company for Q1 2026 stood at -$19.1 million, down from -$18.2 million in the prior quarter.
- The five-year high for Income towards Parent Company was -$11.5 million in Q4 2023, with the low at -$23.5 million in Q2 2023.
- Historically, Income towards Parent Company has averaged -$17.1 million across 5 years, with a median of -$18.0 million in 2023.
- Annual changes were most pronounced in 2022 — Income towards Parent Company plunged 168.9% — and 2023, when it surged 47.47%.
- Ocugen's Income towards Parent Company stood at -$21.9 million in 2022, then jumped by 47.47% to -$11.5 million in 2023, then slipped by 21.76% to -$14.0 million in 2024, then decreased by 29.73% to -$18.2 million in 2025, then dropped by 4.69% to -$19.1 million in 2026.
- The last three Income towards Parent Company figures came in at -$19.1 million (Q1 2026), -$18.2 million (Q4 2025), and -$18.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Ocugen | 411.07 Mn | 411.07 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -19.06 Mn |
| Dec 31, 2025 | -18.21 Mn |
| Sep 30, 2025 | -18.73 Mn |
| Jun 30, 2025 | -14.85 Mn |
| Mar 31, 2025 | -15.46 Mn |
| Dec 31, 2024 | -14.03 Mn |
| Sep 30, 2024 | -12.97 Mn |
| Jun 30, 2024 | -15.28 Mn |
| Mar 31, 2024 | -11.91 Mn |
| Dec 31, 2023 | -11.53 Mn |
| Sep 30, 2023 | -12.43 Mn |
| Jun 30, 2023 | -23.54 Mn |
| Mar 31, 2023 | -18.04 Mn |
| Dec 31, 2022 | -21.94 Mn |
| Sep 30, 2022 | -21.92 Mn |
| Jun 30, 2022 | -21.58 Mn |
| Mar 31, 2022 | -19.03 Mn |
| Dec 31, 2021 | -14.58 Mn |
| Sep 30, 2021 | -10.76 Mn |
| Jun 30, 2021 | -25.62 Mn |